Communication Conundrum: Is Early Drug Safety Disclosure Better?
This article was originally published in RPM Report
Executive Summary
FDA's inaugural quarterly web posting of early safety signals with marketed drugs and biologics has left investors bewildered over how to interpret the listings. But the presence of rigorous risk management programs may be a comforting factor for Wall Street and Big Pharma.